Open EAJA Act of 2010

HR 4717 and S 3122 - legislation to reform the Equal Access to Justice Act in order to increase accountability and transparency

Client expense: $33,957 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE

USCA supported S.3122/H.R.4717, the Open EAJA Act of 2010. This bill directs the Attorney General to issue an annual online report to Congress and the public on the amount of attorney fees and other expenses awarded during the preceding fiscal year pursuant to the law commonly known as the Equal Access to Justice Act (EAJA). USCA opposed presidential use of the American Antiquities Act of 1906 that deviates from the original intent of the Act, which was to protect historic landmarks, historic and prehistoric structures, and other objects of historic or scientific interest in an area confined to the smallest area compatible with proper care and management of the object to be protected. USCA supported H.R.2493 the Judgment Evading Foreign States Accountability Act of 2009. This bill states the policy of the United States regarding: (1) advocacy within the governing bodies of international organizations and other foreign policy settings for the full compensation and fair treatment of persons in whose favor judgments have been awarded by U.S. courts; (2) protection of economic interests of persons and nations that benefit from a reliable flow of foreign capital by restricting the access to U.S. capital markets of judgment evading foreign states (foreign states that fail to fully satisfy a final judgment exceeding a certain amount for more than two years) and their state-owned corporations, warning of the dangers of dealing financially with such states and state-owned corporations, and congressional scrutiny of requests for aid made by such states; and (3) protection of the authority of the U.S. courts by preventing such states from willfully flouting the judgments of those courts. This bill is critical to avoid indirect agriculture subsidies that occur due to loan defaults.

Client expense: Not reported · Firm income: $10,000

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

HR 4717, S 3122 Equal Access to Justice Act

Client expense: Not reported · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE

HR 4717 & S 3122 - legislation to reform the Equal Access to Justice Act in order to increase accountability and transparency

Client expense: $39,236 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.

National monument designations; California CVP & SWP water allocations H.R. 4717, Open EAJA Act, all titles H.R. 6329 & S. 3927, Delta Heritage Area, all titles H.R. 3534, CLEAR Act, all titles

Client expense: $70,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, U.S. Trade Representative (USTR)

HR 4717, S 3122 - EAJA

Client expense: Not reported · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE

HR 4717 & S 3122 - legislation to reform the Equal Access to Justice Act in order to increase accountability and transparency

Client expense: $31,380 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

USCA supported S.3122/H.R.4717, the Open EAJA Act of 2010. This bill directs the Attorney General to issue an annual online report to Congress and the public on the amount of attorney fees and other expenses awarded during the preceding fiscal year pursuant to the law commonly known as the Equal Access to Justice Act (EAJA). USCA opposed presidential use of the American Antiquities Act of 1906 that deviates from the original intent of the Act, which was to protect historic landmarks, historic and prehistoric structures, and other objects of historic or scientific interest in an area confined to the smallest area compatible with proper care and management of the object to be protected. USCA supported H.R.2493 the Judgment Evading Foreign States Accountability Act of 2009. This bill states the policy of the United States regarding: (1) advocacy within the governing bodies of international organizations and other foreign policy settings for the full compensation and fair treatment of persons in whose favor judgments have been awarded by U.S. courts; (2) protection of economic interests of persons and nations that benefit from a reliable flow of foreign capital by restricting the access to U.S. capital markets of judgment evading foreign states (foreign states that fail to fully satisfy a final judgment exceeding a certain amount for more than two years) and their state-owned corporations, warning of the dangers of dealing financially with such states and state-owned corporations, and congressional scrutiny of requests for aid made by such states; and (3) protection of the authority of the U.S. courts by preventing such states from willfully flouting the judgments of those courts. This bill is critical to avoid indirect agriculture subsidies that occur due to loan defaults.

Client expense: Not reported · Firm income: $10,000

1. Opposing legislation that seeks to lock up natural resource and economic assets on millions of acres in the West (including H.R. 980, H.R. 1925, S. 799). 2. Opposing DOI proposed lands designation policies that contemplate unilateral Executive Branch designation of millions of acres of Western Lands. Includes support for legislation that would remove such authority (including H.R. 4716, H.R. 4754, H.R. 4651 and S. 3016, H.R. 4703, H.R. 4675 and S. 3041, H.Res. 1406, H.R. 5580, H.R. 4996, S. 472). 3. Educating policymakers on the implications of the Executive Branch's efforts to establish "projected future climate change-related species vulnerability" as a justification for a broad range of new regulatory actions/powers by agencies of the federal government. 4. Educating policymakers on the importance of a robust minerals policy to support the build-out of the nation's renewables, clean transportation and related sectors. 5. Educating policymakers on the implications of proposed Executive Branch NEPA process revisions to energy and natural resource projects throughout the West. 6. Support for legislation (H.R. 4717 and S. 3122) that seeks to reform the Equal Access to Justice Act, to improve disclosure regarding reimbursements provided to parties -- including environmental advocacy groups -- for litigation against the federal government.

Client expense: Not reported · Firm income: $10,000

Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.

USCA supported Open EAJA Act of 2010. S.3122/H.R.4717- This bill directs the Attorney General to issue an annual online report to Congress and the public on the amount of attorney fees and other expenses awarded during the preceding fiscal year pursuant to the law commonly known as the Equal Access to Justice Act (EAJA). It also directs the Comptroller General to commence an audit of the Equal Access to Justice Act for 1995 through the end of the calendar year in which this Act is enacted, and report to Congress on the audit results.

Client expense: Not reported · Firm income: $10,000

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Justice, Dept of (DOJ), SENATE, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.

1. Opposing legislation that seeks to lock up natural resource and economic assets on millions of acres in the West (including H.R. 980, H.R. 1925/S. 799). 2. Opposing DOI proposed monument policies that contemplate unilateral Executive Branch designation of millions of acres of Western lands. 3. Educating policymakers on the implications of the Administration's effort to establish "projected future climate change-related species vulnerability" as a justification for a broad range of new regulatory actions and powers by agencies of the federal government. 4. Opposing DOI/USFWS Climate Action Plans. 5. Educating policymakers on the importance of a robust minerals policy to support the build-out of the nation's renewables and clean transportation sectors. 6. Educating policymakers on the implications of proposed Administration NEPA process revisions to energy and natural resource projects throughout the West. 7. Support for legislation (H.R. 4717 and S. 3122) that seeks to reform the Equal Access to Justice Act, to improve disclosure regarding reimbursements provided to parties -- including environmental groups -- for litigation against the federal government.

Client expense: Not reported · Firm income: $20,000

Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.

Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.